Prognostic impact of intraductal carcinoma of the prostate and PTEN loss in metastatic castration-sensitive prostate cancer treated with androgen receptor pathway inhibitors

PTEN公司 医学 前列腺癌 张力素 肿瘤科 前列腺 内科学 雄激素剥夺疗法 临床终点 雄激素受体 比例危险模型 比卡鲁胺 活检 泌尿科 癌 雄激素 前列腺活检 生存分析 置信区间 癌症研究 癌症 前列腺切除术 不利影响 PCA3系列 存活率 抗雄激素 临床试验
作者
Shun Sato,Yushi Suhara,Yuya Iwamoto,Kosuke Iwatani,Yu Imai,Kojiro Tashiro,Miyaka Umemori,Jun Miki,Masayuki Shimoda,Takahiro Kimura,Hiroyuki Takahashi
出处
期刊:Japanese Journal of Clinical Oncology [Oxford University Press]
标识
DOI:10.1093/jjco/hyaf214
摘要

Abstract Background Intraductal carcinoma of the prostate (IDC-P) and phosphatase and tensin homolog (PTEN) alteration are established adverse features in prostate cancer. However, their coexistence and prognostic relevance in the era of androgen receptor pathway inhibitor (ARPI) therapy for metastatic castration-sensitive prostate cancer (mCSPC) remain unclear, particularly in Japanese populations. We evaluated the prevalence, concordance, and prognostic significance of IDC-P and PTEN loss in patients with mCSPC treated with ARPI plus androgen deprivation therapy (ADT). Methods We retrospectively analyzed consecutive patients with mCSPC who received ARPI plus ADT between February 2018 and June 2024 across three Japanese institutions. IDC-P was assessed on hematoxylin–eosin–stained biopsy specimens. PTEN loss was defined as ≥90% absence of cytoplasmic staining, consistent with the CAPItello-281 trial criteria. The primary endpoint was castration-resistant prostate cancer–free survival (CRPC-FS). Overall survival was evaluated as a secondary endpoint. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox regression modeling. Results In total, 121 patients were included. IDC-P was identified in 68.6% of biopsy specimens, and PTEN loss in 15.7%. Patients with IDC-P more frequently presented with CHAARTED high-volume and LATITUDE high-risk disease. During a median follow-up of 36 months, 44 patients (36.4%) developed CRPC. IDC-P was independently associated with shorter CRPC-FS [hazard ratio [HR] 2.4, 95% confidence interval (CI) 1.14–5.04; P = .02], whereas PTEN loss was not significantly associated with CRPC-FS or overall survival. Combined assessment of IDC-P and PTEN loss did not demonstrate additive prognostic value. Conclusion In this multicenter Japanese cohort, IDC-P, but not PTEN loss, independently predicted earlier progression to CRPC in patients with mCSPC treated with ARPI plus ADT. The limited overlap between IDC-P and PTEN loss suggests distinct biological mechanisms in Japanese populations. IDC-P remains a strong morphologic indicator of aggressive disease, whereas PTEN loss may serve as a therapeutic biomarker for phosphoinositide 3-kinase/AKT–targeted strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脆升升完成签到,获得积分10
刚刚
布洛芬发布了新的文献求助10
刚刚
1秒前
纯真的坤发布了新的文献求助10
1秒前
2秒前
2秒前
所所的应助被馒头采纳,获得10
2秒前
大个的应助被CoCo采纳,获得10
2秒前
科研通AI6.3的应助被zombie采纳,获得30
3秒前
星辰大海的应助被归离采纳,获得10
3秒前
even发布了新的文献求助10
4秒前
ubless607给神秘墨镜男的求助进行了留言
4秒前
余悲也白完成签到,获得积分10
4秒前
5秒前
EstAffectus发布了新的文献求助30
5秒前
6秒前
小橙子完成签到 ,获得积分10
6秒前
研友_VZG7GZ的应助被我和小张采纳,获得10
7秒前
刘晨完成签到,获得积分10
8秒前
zzz发布了新的文献求助10
9秒前
10秒前
10秒前
困告发布了新的文献求助10
10秒前
打打的应助被guoleileity采纳,获得10
10秒前
隐形曼青的应助被Lemmon_kk采纳,获得10
11秒前
13秒前
14秒前
14秒前
初景的应助被heather采纳,获得20
14秒前
脑洞疼的应助被刘晨采纳,获得10
14秒前
周伦朗发布了新的文献求助10
14秒前
16秒前
领导范儿的应助被zy采纳,获得10
16秒前
打打的应助被yy采纳,获得10
17秒前
斯文败类的应助被困告采纳,获得10
18秒前
大模型的应助被qin202569采纳,获得10
18秒前
steforeca发布了新的文献求助10
18秒前
18秒前
打打的应助被范晨是gay采纳,获得10
19秒前
guangzhui完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573478
关于积分的说明 21831914
捐赠科研通 7781737
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962